Major Players - Rivaroxaban Industry

Aug, 2023 - by CMI

Major Players - Rivaroxaban Industry

Because an anticoagulant medicine is intended to be used for the prevention and treatment of embolism and non-hemorrhagic stroke, rising rates of these medical diseases are likely to drive rivaroxaban market growth over the forecast period. According to the Centres for Disease Control and Prevention (CDC) estimates from 2015, around 900,000 persons in the United States are projected to be afflicted by venous thromboembolism each year. Furthermore, the number of affected individuals in the United States is predicted to rise by 5% to 8% as a result of many genetic risk factors, such as the condition known as hereditary thrombophilia.

 The global Rivaroxaban Market was estimated to be worth US$ 5,653 million in 2017 and is expected to grow at a 1.5% CAGR from 2018 to 2026 due to patent expiry during the forecast period.

Leading Companies of Rivaroxaban Industry:

1. Janssen Pharmaceuticals, Inc: In Raritan, New Jersey, there is a portfolio of drug testing patents. The patent covers diagnostic methods used to determine drug levels in individuals receiving anti-psychotic medicine. Headquarters are in the United States. Anakuria Therapeutics (February 2022), Benevir (May 2018), and XO1 (March 2015) are the most recent acquisitions.

2. Dr. Reddy’s Laboratories Ltd: Established in 1984. Dr. Headquarters are located in Hyderabad, Telangana. Reddy's is one of the world's major generic medication makers. It has a strong presence in North America, which accounts for about half of its generics sales, and it also serves India (22% of its generics sales), Russia (12%), and select European and Latin American countries. Dr. Reddy's also has a strong portfolio of injectables, which account for 25% of its North American sales. Dr. Reddy's Laboratories SA, a wholly-owned subsidiary of Dr. Reddy's Laboratories Ltd., announced on February 27, 2023 that it has entered into a formal deal to purchase Mayne Pharma Group Limited's U.S. generic prescription product portfolio.

3. Anant Pharmaceuticals Pvt. Ltd: Established in 2013. Headquarters are in Delhi, Dr. Anti-counterfeit technology provider for pharmaceutical companies. The organisation delivers an interactive network offering a methodical analytic and diagnostic system to practising doctors, associated health care providers, and patients.

4. Taj Pharmaceuticals Limited: Taj Pharmaceuticals Limited is a public company that was founded on November 5, 2004. It is a non-government corporation that is registered with the Registrar of Companies in Mumbai. It has a paid-up capital of Rs. 10,500,000 and an authorised share capital of Rs. 20,000,000. It is involved in the production of different chemical goods. Taj Pharmaceuticals Limited's Annual General Meeting (AGM) was last convened on 30 September 2022, and its balance statement was last reported on 31 March 2022, according to Ministry of Corporate Affairs (MCA) data.

5. Bayer AG: It was founded in 1863. Dr. Headquarters are located in Leverkusen, Germany. Bayer is a German conglomerate involved in healthcare and agriculture. Healthcare accounts for about half of the company's revenue and comprises prescription medications, vitamins, and other consumer healthcare items. The company has a crop science division that comprises seeds, insecticides, herbicides, and fungicides, which it expanded after acquiring Monsanto.v FarmLead (Jan 2023), Blackford Analysis (Jan 2023), and Targenomix (Nov 2022) are the most recent acquisitions.

*Definition: Rivaroxaban is a novel oral anticoagulant (NOAC) drug. It has several FDA-approved and off-label clinical uses.

© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.